Mayo Clinic

Scaled Insights Inc. is a Toronto-based company specializing in artificial intelligence software that focuses on analyzing human speech to facilitate accessible communication. Established in 2015, the company has developed a unique Behavioral AI technology aimed at improving interactions in various industries, including healthcare, fintech, insurtech, and human resources. Its offerings enable users to manage insurance claims, align financial advisors with clients, identify high performers, and foster better communication regarding health and wellness. The software is particularly beneficial for clinicians, allowing them to understand patient personalities and provide personalized coaching to promote healthier behaviors. By analyzing complex human behavior data, Scaled Insights helps organizations optimize operations and make informed, data-driven decisions to enhance patient outcomes and reduce costs. Additionally, the company has an office in Leeds, United Kingdom, further expanding its operational reach.

Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.

JOGO Health is a virtual care company that specializes in digital therapeutics aimed at treating pain, neuromuscular conditions, and pelvic floor disorders. Utilizing clinically proven digital interventions, the company develops an AI-driven mobile app paired with wearable sensors that deliver tailored treatment protocols. These offerings include games and exercises designed for muscle relaxation, movement coordination, and neuromuscular reeducation, all leveraging the brain's neuroplasticity. By enhancing patient adherence to rehabilitation programs, JOGO Health enables healthcare providers to achieve improved health outcomes for conditions such as chronic pain, stroke recovery, and pelvic health issues.

AccuLine is a digital health company dedicated to early detection of coronary artery disease. It develops CORA, a smart, accurate, and user-friendly exam designed to replace traditional ECG stress tests, enabling healthcare providers to prevent heart attacks more effectively.

PinkDx is a biotechnology company specializing in women's health. It develops molecular tests to improve diagnostic outcomes for women with vague gynecological cancer symptoms, offering alternatives to invasive procedures. This enables more comfortable and efficient resolution of health concerns, providing timely and positive impacts on patients' lives.

AccuLine is a digital health company dedicated to early detection of coronary artery disease. It develops CORA, a smart, accurate, and user-friendly exam designed to replace traditional ECG stress tests, enabling healthcare providers to prevent heart attacks more effectively.

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

AccurKardia is an innovative company specializing in ECG-led diagnostics software. It transforms ECG data into a powerful tool to improve patient outcomes globally, with initial applications in cardiology. The company offers AccurECG™, an FDA-cleared Class II software as a medical device (SaMD) for automated, near real-time ECG interpretation. Its AI-driven hyperkalemia detection solution, AK+ Guard™, received FDA Breakthrough Device Designation.

Lucem Health is a company that specializes in remote diagnostics through an innovative platform that connects patient telemetry and biosensing devices with artificial intelligence algorithms. The platform is designed to facilitate data ingestion, orchestration, and connectivity, which enhances continuous care for patients while allowing them greater control over their health. Additionally, Lucem Health supports the development and deployment of clinical AI models, enabling healthcare providers to integrate AI-generated insights into their workflows. This capability allows clinicians to improve care delivery by better understanding the impact of these insights on patient outcomes. Overall, Lucem Health aims to enhance the effectiveness of healthcare through advanced technology and data-driven solutions.

Mediwhale is a healthcare company focused on preventive medicine through innovative AI technology. The company has developed a unique AI screening platform that utilizes retinal scans for non-invasive risk assessments and diagnoses related to cardiovascular, renal, metabolic health, and eye diseases. Mediwhale's platform includes RetiCVD® for cardiovascular disease risk assessment, RetiCKD® for chronic kidney disease risk assessment, and RetiEYE® for detecting referable eye diseases. These tools have been clinically validated through collaborations with medical institutions across multiple countries and are recognized for their accuracy in predicting health risks before symptoms appear.

Healium is a technology company that develops mental fitness tools and immersive, bio-data-driven experiences to support self-management of anxiety, sleep issues, burnout, and overall well-being. The platform links real-time biometric data from wearables such as heart rate and brain activity via EEG headbands to personalized video or VR assets, producing reactive media escapes controlled by the user’s physiology. By integrating wearable devices and sensors, Healium delivers data-driven content that adapts to the user in real time, aiming to reduce anxiety, improve mood, and build resilience for individuals and organizations. Peer-reviewed studies have reported rapid mood benefits and anxiety reduction in as little as four minutes.

Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.

Genomadix specializes in developing molecular tests for infectious diseases, precision medicine, and water safety. Its innovative platform and portable analyzer use PCR technology to deliver swift, accurate test results outside traditional healthcare settings.

Olive Diagnostics is a company that has developed an innovative passive urine analysis sensor designed to enhance early disease detection and chronic disease management. This sensor, which can be easily mounted to any toilet, utilizes spectroscopy combined with artificial intelligence-based analytics to monitor the urine stream. By continuously collecting and analyzing health data, the device provides users with real-time health alerts that promote awareness of their bodily functions. The technology not only supports individual health management but also offers valuable insights for pharmaceutical and contract research organizations to track drug compliance and usage. With its focus on proactive health monitoring, Olive Diagnostics aims to make urine lab services accessible even in nonindustrial nations, thereby transforming personal health care through advanced, continuous biomarker tracking.

Karkinos Healthcare is a technology-driven oncology-focused managed health care platform that supports early detection and diagnosis of common cancers and aims to extend cancer care to patients at home. The platform connects patients with healthcare providers, technicians, researchers, and oncologists to enable personalized insights, precision medicine, and coordinated care across the care continuum, creating an accessible and effective cancer care ecosystem.

Medically Home Group, Inc. is a Boston-based company that specializes in providing a virtual hospital program designed to deliver in-home medical care services. Founded in 2016, the company focuses on shifting medical care from traditional hospital settings to patients' homes, particularly for those with serious or complex illnesses such as heart failure, pneumonia, and respiratory infections. Medically Home's technology-enabled platform connects patients with caregivers, facilitating ongoing monitoring and communication. This system allows patients and their families to access a centralized medical command center, which offers on-demand acute medical care management, ensuring that necessary medical support is available in a more comfortable and familiar environment.

JOGO Health is a virtual care company that specializes in digital therapeutics aimed at treating pain, neuromuscular conditions, and pelvic floor disorders. Utilizing clinically proven digital interventions, the company develops an AI-driven mobile app paired with wearable sensors that deliver tailored treatment protocols. These offerings include games and exercises designed for muscle relaxation, movement coordination, and neuromuscular reeducation, all leveraging the brain's neuroplasticity. By enhancing patient adherence to rehabilitation programs, JOGO Health enables healthcare providers to achieve improved health outcomes for conditions such as chronic pain, stroke recovery, and pelvic health issues.

Medically Home Group, Inc. is a Boston-based company that specializes in providing a virtual hospital program designed to deliver in-home medical care services. Founded in 2016, the company focuses on shifting medical care from traditional hospital settings to patients' homes, particularly for those with serious or complex illnesses such as heart failure, pneumonia, and respiratory infections. Medically Home's technology-enabled platform connects patients with caregivers, facilitating ongoing monitoring and communication. This system allows patients and their families to access a centralized medical command center, which offers on-demand acute medical care management, ensuring that necessary medical support is available in a more comfortable and familiar environment.

Securisyn Medical manufactures and supplies oxygen delivery systems for mechanically ventilated patients in critical care settings. Its innovative airway stabilization system, featuring a ribbed endotracheal tube and interlocking stabilizer, enhances patient safety by preventing unplanned extubation and reducing healthcare costs.

Progentec Diagnostics, Inc. is a company focused on developing innovative diagnostic tests for managing systemic lupus erythematosus (SLE). Established in 2015 and headquartered in Oklahoma City, Oklahoma, the company has created the aiSLE DX platform, which offers tools like a flare prediction score to measure disease activity in SLE patients and an early diagnostic test for lupus. Progentec integrates advanced technology and collaborates with research institutions globally, aiming to address significant unmet needs in diagnostic interventions. The company's mission centers on improving disease management and reducing disease incidence through enhanced screening and early detection.

Elysium Health, Inc., established in 2014 and headquartered in New York, specializes in the development and sale of health supplements. The company focuses on two primary areas: cellular health and optimization, and long-term brain health. It offers a proprietary formulation of natural compounds, designed to support overall well-being at the cellular level, which is sold directly to consumers via its online platform. Additionally, Elysium provides a biological age testing solution.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Ambient Clinical Analytics, Inc. is a healthcare technology company specializing in data assimilation, communication, and analytics for clinical decision support. Based in Rochester, Minnesota, the company develops tools tailored for use in intensive care units, operating rooms, and emergency departments. Its flagship product, AWARE, integrates with various electronic health record systems and bedside monitors to deliver critical patient information on a unified dashboard. Additionally, Ambient offers the Mayo Clinic YES Board, a multi-patient management tool that enhances situational awareness and streamlines patient flow. The company also provides specialized solutions such as Sepsis DART for real-time sepsis detection and the Ventilator-Induced Lung Injury Sniffer for monitoring ventilator patients. Furthermore, the Synthesis Platform serves as an integration hub for AWARE and the Mayo Clinic tools, facilitating seamless data exchange. Ambient Clinical Analytics was founded in 2013 and focuses on improving patient outcomes while reducing healthcare costs through innovative technology.

Founded in 2012, Geneticure develops pharmacogenetic testing tools that enable healthcare providers to offer personalized medicine. Its flagship product is a cheek-swab test predicting individual responses to high blood pressure medications and devices.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Progentec Diagnostics, Inc. is a company focused on developing innovative diagnostic tests for managing systemic lupus erythematosus (SLE). Established in 2015 and headquartered in Oklahoma City, Oklahoma, the company has created the aiSLE DX platform, which offers tools like a flare prediction score to measure disease activity in SLE patients and an early diagnostic test for lupus. Progentec integrates advanced technology and collaborates with research institutions globally, aiming to address significant unmet needs in diagnostic interventions. The company's mission centers on improving disease management and reducing disease incidence through enhanced screening and early detection.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

DayTwo Ltd. is a precision nutrition company based in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome analysis to provide tailored health solutions for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo utilizes a web-based platform that offers personalized dietary recommendations through its innovative Food Prescriptions™, which are designed to help individuals manage their blood sugar levels and improve overall health. By sequencing gut microbiomes, the company identifies how different foods affect each person, allowing for customized nutrition plans. DayTwo's virtual care model is supported by Certified Diabetes Care and Education Specialists and Registered Dietitians, who engage with patients through a smartphone application to track progress and ensure adherence to the dietary recommendations.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Lifecode, Inc. is a molecular diagnostics company based in Foster City, California, specializing in next-generation sequencing (NGS) technology. The company develops a range of NGS-based cancer assays, including its flagship product, the Lifecode Pan Cancer Somatic Panel, which is designed for use in various metastatic and rare cancers, as well as for patients seeking clinical trials. Lifecode focuses on translating complex genomic and therapeutic data into actionable insights for healthcare providers, patients, and payers. The company's team comprises experts in data science, software engineering, computational biology, bioinformatics, machine learning, molecular biology, and pathology, enabling it to bridge the gap between advanced sequencing technology and clinical application. Lifecode was previously known as Silicon Valley Biosystems, Inc. and rebranded in 2015. As of early 2016, it operates as a subsidiary of MedGenome Labs Private Ltd.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Ambient Clinical Analytics, Inc. is a healthcare technology company specializing in data assimilation, communication, and analytics for clinical decision support. Based in Rochester, Minnesota, the company develops tools tailored for use in intensive care units, operating rooms, and emergency departments. Its flagship product, AWARE, integrates with various electronic health record systems and bedside monitors to deliver critical patient information on a unified dashboard. Additionally, Ambient offers the Mayo Clinic YES Board, a multi-patient management tool that enhances situational awareness and streamlines patient flow. The company also provides specialized solutions such as Sepsis DART for real-time sepsis detection and the Ventilator-Induced Lung Injury Sniffer for monitoring ventilator patients. Furthermore, the Synthesis Platform serves as an integration hub for AWARE and the Mayo Clinic tools, facilitating seamless data exchange. Ambient Clinical Analytics was founded in 2013 and focuses on improving patient outcomes while reducing healthcare costs through innovative technology.

The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...

Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.

Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.